Loading…
Prolonged Insulin Independence After Islet Allotransplants in Recipients with Type 1 Diabetes
We sought to determine the long‐term outcomes in type 1 diabetic recipients of intraportal alloislet transplants on a modified immunosuppressive protocol. Six recipients with hypoglycemia unawareness received one to two islet infusions. Induction therapy was with antithymocyte globulin (ATG) plus et...
Saved in:
| Published in: | American journal of transplantation 2008-11, Vol.8 (11), p.2463-2470 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5334-1a8c89af717651ddf7d222c196f0f4e939536f24a273b3c453f88f8cfcc7c6a23 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5334-1a8c89af717651ddf7d222c196f0f4e939536f24a273b3c453f88f8cfcc7c6a23 |
| container_end_page | 2470 |
| container_issue | 11 |
| container_start_page | 2463 |
| container_title | American journal of transplantation |
| container_volume | 8 |
| creator | Bellin, M. D. Kandaswamy, R. Parkey, J. Zhang, H.‐J. Liu, B. Ihm, S. H. Ansite, J. D. Witson, J. Bansal‐Pakala, P. Balamurugan, A. N. Papas, K. Sutherland, D. E. R. Moran, A. Hering, B. J. |
| description | We sought to determine the long‐term outcomes in type 1 diabetic recipients of intraportal alloislet transplants on a modified immunosuppressive protocol. Six recipients with hypoglycemia unawareness received one to two islet infusions. Induction therapy was with antithymocyte globulin (ATG) plus etanercept for tumor necrosis factor‐α blockade. Recipients received cyclosporine and everolimus for maintenance immunosuppression for the first year posttransplant, with mycophenolic acid or mycophenolate mofetil subsequently substituted for everolimus. Recipients have been followed for 1173 ± 270 days since their last infusion for islet graft function (insulin independence, hemoglobin A1c levels and C‐peptide production) and for adverse events associated with the study protocol. Of the six recipients, five were insulin‐independent at 1 year, and four continue to be insulin‐independent at a mean of 3.4 ± 0.4 years posttransplant. None of the six recipients experienced recurrence of severe hypoglycemia. Measured glomerular filtration rate decreased from 110.5 ± 21.2 mL/min/1.73 m2 pretransplant to 82.6 ±19.1 mL/min/1.73 m2 at 1 year posttransplant. In conclusion, islet transplants restored insulin independence for a mean of >3 years in four of six recipients treated with ATG and etanercept induction therapy and with cyclosporine and, initially, everolimus for maintenance. Our results suggest this immunosuppressive protocol may allow long‐term graft survival.
In 4 of 6 type 1 diabetic islet allotransplant recipients treated with ATG and etanercept induction therapy and with cyclosporine and, initially, everolimus for maintenance, insulin independence was maintained for a mean of >3 years. |
| doi_str_mv | 10.1111/j.1600-6143.2008.02404.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4312281</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69674223</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5334-1a8c89af717651ddf7d222c196f0f4e939536f24a273b3c453f88f8cfcc7c6a23</originalsourceid><addsrcrecordid>eNqNkU1PGzEQhq0KVCjtX6h8gVu2_lqv91CkCGgbhERVpcfKcrxjcOTsbu0NkH9fbxOFcio-eMaaZ0bv-EUIU1LQfD4tCyoJmUgqeMEIUQVhgoji6Q063hcO9jkvj9C7lJaE0Iop9hYdUaWIEkQdo1_fYxe69g4aPGvTOvg2xwZ6yFdrAU_dABHPUoABT0Pohmja1AfTDgln9gdY33sYX49-uMfzTQ-Y4ktvFjBAeo8OnQkJPuziCfr55Wp-8W1yc_t1djG9mdiSczGhRllVG1fRSpa0aVzVMMYsraUjTkDN65JLx4RhFV9wK0rulHLKOmsrKw3jJ-h8O7dfL1bQ2CwomqD76FcmbnRnvH5Zaf29vusetOCUMUXzgLPdgNj9XkMa9MonCyEvCt06aVnLSjDG_wtmzVSWSmVQbUEbu5QiuL0aSvRool7q0R89eqVHE_VfE_VTbv347zbPjTvXMnC6A0yyJrjsifVpzzGimODV-C2ft9yjD7B5tQA9vZ6PGf8DWl249w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19616588</pqid></control><display><type>article</type><title>Prolonged Insulin Independence After Islet Allotransplants in Recipients with Type 1 Diabetes</title><source>Wiley</source><source>ScienceDirect - Connect here FIRST to enable access</source><creator>Bellin, M. D. ; Kandaswamy, R. ; Parkey, J. ; Zhang, H.‐J. ; Liu, B. ; Ihm, S. H. ; Ansite, J. D. ; Witson, J. ; Bansal‐Pakala, P. ; Balamurugan, A. N. ; Papas, K. ; Sutherland, D. E. R. ; Moran, A. ; Hering, B. J.</creator><creatorcontrib>Bellin, M. D. ; Kandaswamy, R. ; Parkey, J. ; Zhang, H.‐J. ; Liu, B. ; Ihm, S. H. ; Ansite, J. D. ; Witson, J. ; Bansal‐Pakala, P. ; Balamurugan, A. N. ; Papas, K. ; Sutherland, D. E. R. ; Moran, A. ; Hering, B. J.</creatorcontrib><description>We sought to determine the long‐term outcomes in type 1 diabetic recipients of intraportal alloislet transplants on a modified immunosuppressive protocol. Six recipients with hypoglycemia unawareness received one to two islet infusions. Induction therapy was with antithymocyte globulin (ATG) plus etanercept for tumor necrosis factor‐α blockade. Recipients received cyclosporine and everolimus for maintenance immunosuppression for the first year posttransplant, with mycophenolic acid or mycophenolate mofetil subsequently substituted for everolimus. Recipients have been followed for 1173 ± 270 days since their last infusion for islet graft function (insulin independence, hemoglobin A1c levels and C‐peptide production) and for adverse events associated with the study protocol. Of the six recipients, five were insulin‐independent at 1 year, and four continue to be insulin‐independent at a mean of 3.4 ± 0.4 years posttransplant. None of the six recipients experienced recurrence of severe hypoglycemia. Measured glomerular filtration rate decreased from 110.5 ± 21.2 mL/min/1.73 m2 pretransplant to 82.6 ±19.1 mL/min/1.73 m2 at 1 year posttransplant. In conclusion, islet transplants restored insulin independence for a mean of >3 years in four of six recipients treated with ATG and etanercept induction therapy and with cyclosporine and, initially, everolimus for maintenance. Our results suggest this immunosuppressive protocol may allow long‐term graft survival.
In 4 of 6 type 1 diabetic islet allotransplant recipients treated with ATG and etanercept induction therapy and with cyclosporine and, initially, everolimus for maintenance, insulin independence was maintained for a mean of >3 years.</description><identifier>ISSN: 1600-6135</identifier><identifier>EISSN: 1600-6143</identifier><identifier>DOI: 10.1111/j.1600-6143.2008.02404.x</identifier><identifier>PMID: 18808408</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Adult ; Allograft survival ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antilymphocyte Serum - therapeutic use ; Biological and medical sciences ; Cyclosporine - therapeutic use ; Diabetes Mellitus, Type 1 - therapy ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etanercept ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Everolimus ; Female ; Humans ; Immunoglobulin G - therapeutic use ; Immunosuppressive Agents - therapeutic use ; Insulin - metabolism ; islet graft ; islet transplantation ; islets ; Islets of Langerhans - cytology ; Islets of Langerhans Transplantation - methods ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Receptors, Tumor Necrosis Factor - therapeutic use ; Recurrence ; Sirolimus - analogs & derivatives ; Sirolimus - therapeutic use ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; thymoglobulin ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>American journal of transplantation, 2008-11, Vol.8 (11), p.2463-2470</ispartof><rights>2008 The Authors Journal compilation © 2008 The American Society of Transplantation and the American Society of Transplant Surgeons</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5334-1a8c89af717651ddf7d222c196f0f4e939536f24a273b3c453f88f8cfcc7c6a23</citedby><cites>FETCH-LOGICAL-c5334-1a8c89af717651ddf7d222c196f0f4e939536f24a273b3c453f88f8cfcc7c6a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-6143.2008.02404.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-6143.2008.02404.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,315,786,790,891,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20824372$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18808408$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bellin, M. D.</creatorcontrib><creatorcontrib>Kandaswamy, R.</creatorcontrib><creatorcontrib>Parkey, J.</creatorcontrib><creatorcontrib>Zhang, H.‐J.</creatorcontrib><creatorcontrib>Liu, B.</creatorcontrib><creatorcontrib>Ihm, S. H.</creatorcontrib><creatorcontrib>Ansite, J. D.</creatorcontrib><creatorcontrib>Witson, J.</creatorcontrib><creatorcontrib>Bansal‐Pakala, P.</creatorcontrib><creatorcontrib>Balamurugan, A. N.</creatorcontrib><creatorcontrib>Papas, K.</creatorcontrib><creatorcontrib>Sutherland, D. E. R.</creatorcontrib><creatorcontrib>Moran, A.</creatorcontrib><creatorcontrib>Hering, B. J.</creatorcontrib><title>Prolonged Insulin Independence After Islet Allotransplants in Recipients with Type 1 Diabetes</title><title>American journal of transplantation</title><addtitle>Am J Transplant</addtitle><description>We sought to determine the long‐term outcomes in type 1 diabetic recipients of intraportal alloislet transplants on a modified immunosuppressive protocol. Six recipients with hypoglycemia unawareness received one to two islet infusions. Induction therapy was with antithymocyte globulin (ATG) plus etanercept for tumor necrosis factor‐α blockade. Recipients received cyclosporine and everolimus for maintenance immunosuppression for the first year posttransplant, with mycophenolic acid or mycophenolate mofetil subsequently substituted for everolimus. Recipients have been followed for 1173 ± 270 days since their last infusion for islet graft function (insulin independence, hemoglobin A1c levels and C‐peptide production) and for adverse events associated with the study protocol. Of the six recipients, five were insulin‐independent at 1 year, and four continue to be insulin‐independent at a mean of 3.4 ± 0.4 years posttransplant. None of the six recipients experienced recurrence of severe hypoglycemia. Measured glomerular filtration rate decreased from 110.5 ± 21.2 mL/min/1.73 m2 pretransplant to 82.6 ±19.1 mL/min/1.73 m2 at 1 year posttransplant. In conclusion, islet transplants restored insulin independence for a mean of >3 years in four of six recipients treated with ATG and etanercept induction therapy and with cyclosporine and, initially, everolimus for maintenance. Our results suggest this immunosuppressive protocol may allow long‐term graft survival.
In 4 of 6 type 1 diabetic islet allotransplant recipients treated with ATG and etanercept induction therapy and with cyclosporine and, initially, everolimus for maintenance, insulin independence was maintained for a mean of >3 years.</description><subject>Adult</subject><subject>Allograft survival</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antilymphocyte Serum - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cyclosporine - therapeutic use</subject><subject>Diabetes Mellitus, Type 1 - therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etanercept</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Everolimus</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Insulin - metabolism</subject><subject>islet graft</subject><subject>islet transplantation</subject><subject>islets</subject><subject>Islets of Langerhans - cytology</subject><subject>Islets of Langerhans Transplantation - methods</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Recurrence</subject><subject>Sirolimus - analogs & derivatives</subject><subject>Sirolimus - therapeutic use</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>thymoglobulin</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>1600-6135</issn><issn>1600-6143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqNkU1PGzEQhq0KVCjtX6h8gVu2_lqv91CkCGgbhERVpcfKcrxjcOTsbu0NkH9fbxOFcio-eMaaZ0bv-EUIU1LQfD4tCyoJmUgqeMEIUQVhgoji6Q063hcO9jkvj9C7lJaE0Iop9hYdUaWIEkQdo1_fYxe69g4aPGvTOvg2xwZ6yFdrAU_dABHPUoABT0Pohmja1AfTDgln9gdY33sYX49-uMfzTQ-Y4ktvFjBAeo8OnQkJPuziCfr55Wp-8W1yc_t1djG9mdiSczGhRllVG1fRSpa0aVzVMMYsraUjTkDN65JLx4RhFV9wK0rulHLKOmsrKw3jJ-h8O7dfL1bQ2CwomqD76FcmbnRnvH5Zaf29vusetOCUMUXzgLPdgNj9XkMa9MonCyEvCt06aVnLSjDG_wtmzVSWSmVQbUEbu5QiuL0aSvRool7q0R89eqVHE_VfE_VTbv347zbPjTvXMnC6A0yyJrjsifVpzzGimODV-C2ft9yjD7B5tQA9vZ6PGf8DWl249w</recordid><startdate>200811</startdate><enddate>200811</enddate><creator>Bellin, M. D.</creator><creator>Kandaswamy, R.</creator><creator>Parkey, J.</creator><creator>Zhang, H.‐J.</creator><creator>Liu, B.</creator><creator>Ihm, S. H.</creator><creator>Ansite, J. D.</creator><creator>Witson, J.</creator><creator>Bansal‐Pakala, P.</creator><creator>Balamurugan, A. N.</creator><creator>Papas, K.</creator><creator>Sutherland, D. E. R.</creator><creator>Moran, A.</creator><creator>Hering, B. J.</creator><general>Blackwell Publishing Inc</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200811</creationdate><title>Prolonged Insulin Independence After Islet Allotransplants in Recipients with Type 1 Diabetes</title><author>Bellin, M. D. ; Kandaswamy, R. ; Parkey, J. ; Zhang, H.‐J. ; Liu, B. ; Ihm, S. H. ; Ansite, J. D. ; Witson, J. ; Bansal‐Pakala, P. ; Balamurugan, A. N. ; Papas, K. ; Sutherland, D. E. R. ; Moran, A. ; Hering, B. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5334-1a8c89af717651ddf7d222c196f0f4e939536f24a273b3c453f88f8cfcc7c6a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Allograft survival</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antilymphocyte Serum - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cyclosporine - therapeutic use</topic><topic>Diabetes Mellitus, Type 1 - therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etanercept</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Everolimus</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Insulin - metabolism</topic><topic>islet graft</topic><topic>islet transplantation</topic><topic>islets</topic><topic>Islets of Langerhans - cytology</topic><topic>Islets of Langerhans Transplantation - methods</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Recurrence</topic><topic>Sirolimus - analogs & derivatives</topic><topic>Sirolimus - therapeutic use</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>thymoglobulin</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bellin, M. D.</creatorcontrib><creatorcontrib>Kandaswamy, R.</creatorcontrib><creatorcontrib>Parkey, J.</creatorcontrib><creatorcontrib>Zhang, H.‐J.</creatorcontrib><creatorcontrib>Liu, B.</creatorcontrib><creatorcontrib>Ihm, S. H.</creatorcontrib><creatorcontrib>Ansite, J. D.</creatorcontrib><creatorcontrib>Witson, J.</creatorcontrib><creatorcontrib>Bansal‐Pakala, P.</creatorcontrib><creatorcontrib>Balamurugan, A. N.</creatorcontrib><creatorcontrib>Papas, K.</creatorcontrib><creatorcontrib>Sutherland, D. E. R.</creatorcontrib><creatorcontrib>Moran, A.</creatorcontrib><creatorcontrib>Hering, B. J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bellin, M. D.</au><au>Kandaswamy, R.</au><au>Parkey, J.</au><au>Zhang, H.‐J.</au><au>Liu, B.</au><au>Ihm, S. H.</au><au>Ansite, J. D.</au><au>Witson, J.</au><au>Bansal‐Pakala, P.</au><au>Balamurugan, A. N.</au><au>Papas, K.</au><au>Sutherland, D. E. R.</au><au>Moran, A.</au><au>Hering, B. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolonged Insulin Independence After Islet Allotransplants in Recipients with Type 1 Diabetes</atitle><jtitle>American journal of transplantation</jtitle><addtitle>Am J Transplant</addtitle><date>2008-11</date><risdate>2008</risdate><volume>8</volume><issue>11</issue><spage>2463</spage><epage>2470</epage><pages>2463-2470</pages><issn>1600-6135</issn><eissn>1600-6143</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>content type line 23</notes><notes>ObjectType-Article-1</notes><notes>ObjectType-Feature-2</notes><abstract>We sought to determine the long‐term outcomes in type 1 diabetic recipients of intraportal alloislet transplants on a modified immunosuppressive protocol. Six recipients with hypoglycemia unawareness received one to two islet infusions. Induction therapy was with antithymocyte globulin (ATG) plus etanercept for tumor necrosis factor‐α blockade. Recipients received cyclosporine and everolimus for maintenance immunosuppression for the first year posttransplant, with mycophenolic acid or mycophenolate mofetil subsequently substituted for everolimus. Recipients have been followed for 1173 ± 270 days since their last infusion for islet graft function (insulin independence, hemoglobin A1c levels and C‐peptide production) and for adverse events associated with the study protocol. Of the six recipients, five were insulin‐independent at 1 year, and four continue to be insulin‐independent at a mean of 3.4 ± 0.4 years posttransplant. None of the six recipients experienced recurrence of severe hypoglycemia. Measured glomerular filtration rate decreased from 110.5 ± 21.2 mL/min/1.73 m2 pretransplant to 82.6 ±19.1 mL/min/1.73 m2 at 1 year posttransplant. In conclusion, islet transplants restored insulin independence for a mean of >3 years in four of six recipients treated with ATG and etanercept induction therapy and with cyclosporine and, initially, everolimus for maintenance. Our results suggest this immunosuppressive protocol may allow long‐term graft survival.
In 4 of 6 type 1 diabetic islet allotransplant recipients treated with ATG and etanercept induction therapy and with cyclosporine and, initially, everolimus for maintenance, insulin independence was maintained for a mean of >3 years.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>18808408</pmid><doi>10.1111/j.1600-6143.2008.02404.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1600-6135 |
| ispartof | American journal of transplantation, 2008-11, Vol.8 (11), p.2463-2470 |
| issn | 1600-6135 1600-6143 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4312281 |
| source | Wiley; ScienceDirect - Connect here FIRST to enable access |
| subjects | Adult Allograft survival Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antilymphocyte Serum - therapeutic use Biological and medical sciences Cyclosporine - therapeutic use Diabetes Mellitus, Type 1 - therapy Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etanercept Etiopathogenesis. Screening. Investigations. Target tissue resistance Everolimus Female Humans Immunoglobulin G - therapeutic use Immunosuppressive Agents - therapeutic use Insulin - metabolism islet graft islet transplantation islets Islets of Langerhans - cytology Islets of Langerhans Transplantation - methods Male Medical sciences Middle Aged Pharmacology. Drug treatments Receptors, Tumor Necrosis Factor - therapeutic use Recurrence Sirolimus - analogs & derivatives Sirolimus - therapeutic use Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases thymoglobulin Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Prolonged Insulin Independence After Islet Allotransplants in Recipients with Type 1 Diabetes |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T02%3A41%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolonged%20Insulin%20Independence%20After%20Islet%20Allotransplants%20in%20Recipients%20with%20Type%201%20Diabetes&rft.jtitle=American%20journal%20of%20transplantation&rft.au=Bellin,%20M.%20D.&rft.date=2008-11&rft.volume=8&rft.issue=11&rft.spage=2463&rft.epage=2470&rft.pages=2463-2470&rft.issn=1600-6135&rft.eissn=1600-6143&rft_id=info:doi/10.1111/j.1600-6143.2008.02404.x&rft_dat=%3Cproquest_pubme%3E69674223%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5334-1a8c89af717651ddf7d222c196f0f4e939536f24a273b3c453f88f8cfcc7c6a23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19616588&rft_id=info:pmid/18808408&rfr_iscdi=true |